GuineaTuberculosis profile
Population  2015 13 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 3.6 (2.1–5.4) 28 (17–43)
Mortality (HIV+TB only) 1.9 (1.3–2.8) 15 (10–22)
Incidence  (includes HIV+TB) 22 (14–32) 177 (114–252)
Incidence (HIV+TB only) 5.4 (3.5–7.9) 43 (27–63)
Incidence (MDR/RR-TB)** 0.78 (0–1.7) 6.2 (0–13)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 1.2 (0.36–2) 6 (1.5–11) 7.3 (1.8–13)
Males 1.7 (0.99–2.3) 13 (9.1–18) 15 (10–20)
Total 2.9 (1.9–3.9) 19 (15–24) 22 (14–32)
TB case notifications, 2015  
Total cases notified 12 242
Total new and relapse 12 154
          - % tested with rapid diagnostics at time of diagnosis <1%
          - % with known HIV status 79%
          - % pulmonary 78%
          - % bacteriologically confirmed among pulmonary 84%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 55% (38–84)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.26 (0.15–0.42)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 2 332 24%
          - on antiretroviral therapy 1 601 69%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  370
(0–740)
Estimated % of TB cases with MDR/RR-TB 2.8% (0.1–6.7) 21% (2.2–39)  
% notified tested for rifampicin resistance 1% 36% 315
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 123, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 34, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 83% 11 117
Previously treated cases, excluding relapse, registered in 2014 66% 270
HIV-positive TB cases, all types, registered in 2014 77% 2 067
MDR/RR-TB cases started on second-line treatment in 2013 58% 53
XDR-TB cases started on second-line treatment in 2013   0
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2016  
National TB budget (US$ millions) 3.3
Funding source: 26% domestic, 36% international, 37% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-06 Data: www.who.int/tb/data